Synaptogenix PE Ratio 2020-2025 | TAOX
Current and historical p/e ratio for Synaptogenix (TAOX) from 2020 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Synaptogenix PE ratio as of July 02, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Synaptogenix PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-07-02 |
8.08 |
|
0.00 |
| 2025-03-31 |
2.42 |
$-10.08 |
0.00 |
| 2024-12-31 |
3.47 |
$-10.53 |
0.00 |
| 2024-09-30 |
3.02 |
$-6.17 |
0.00 |
| 2024-06-30 |
4.10 |
$-2.34 |
0.00 |
| 2024-03-31 |
4.69 |
$-35.91 |
0.00 |
| 2023-12-31 |
6.80 |
$-42.00 |
0.00 |
| 2023-09-30 |
11.00 |
$-26.25 |
0.00 |
| 2023-06-30 |
23.19 |
$-36.25 |
0.00 |
| 2023-03-31 |
20.00 |
$-15.00 |
0.00 |
| 2022-12-31 |
29.00 |
$-20.25 |
0.00 |
| 2022-09-30 |
167.50 |
$-51.50 |
0.00 |
| 2022-06-30 |
129.75 |
$-52.50 |
0.00 |
| 2022-03-31 |
193.50 |
$-53.50 |
0.00 |
| 2021-12-31 |
212.75 |
$-48.50 |
0.00 |
| 2021-09-30 |
248.50 |
$-33.00 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.011B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
